Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 …
…, O Rosmorduc, V Breder, R Gerolami, G Masi, PJ Ross… - The Lancet, 2017 - thelancet.com
Background There are no systemic treatments for patients with hepatocellular carcinoma (HCC)
whose disease progresses during sorafenib treatment. We aimed to assess the efficacy …
whose disease progresses during sorafenib treatment. We aimed to assess the efficacy …
Transferring the blues: depression-associated gut microbiota induces neurobehavioural changes in the rat
…, AE Hoban, L Scott, P Fitzgerald, P Ross… - Journal of psychiatric …, 2016 - Elsevier
The gut microbiota interacts with the host via neuroimmune, neuroendocrine and neural
pathways. These pathways are components of the brain-gut-microbiota axis and preclinical …
pathways. These pathways are components of the brain-gut-microbiota axis and preclinical …
Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging–defined poor-risk …
…, AR Norman, N Tebbutt, M Hill, PJ Ross… - Journal of Clinical …, 2006 - ascopubs.org
Purpose To evaluate neoadjuvant capecitabine/oxaliplatin before chemoradiotherapy (CRT)
and total mesorectal excision (TME) in newly diagnosed patients with magnetic resonance …
and total mesorectal excision (TME) in newly diagnosed patients with magnetic resonance …
[HTML][HTML] Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre …
…, JR Izbicki, GW Middleton, S Cummins, PJ Ross… - The Lancet, 2017 - thelancet.com
Background The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care
based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients …
based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients …
Bacteriocins: biological tools for bio-preservation and shelf-life extension
The lactococcal bacteriocin named nisin (or group N inhibitory substance) was first marketed
in England in 1953 and since then has been approved for use in over 48 countries. The …
in England in 1953 and since then has been approved for use in over 48 countries. The …
[HTML][HTML] Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled …
A Lamarca, DH Palmer, HS Wasan, PJ Ross… - The Lancet …, 2021 - thelancet.com
Background Advanced biliary tract cancer has a poor prognosis. Cisplatin and gemcitabine
is the standard first-line chemotherapy regimen, but no robust evidence is available for …
is the standard first-line chemotherapy regimen, but no robust evidence is available for …
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global …
…, C Prasad, KM Rau, JL Raoul, D Richards, P Ross… - The Lancet, 2016 - thelancet.com
Background Nanoliposomal irinotecan showed activity in a phase 2 study in patients with
metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based …
metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based …
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
…, S Falk, M Finch-Jones, H Wasan, P Ross… - The Lancet …, 2019 - thelancet.com
Background Despite improvements in multidisciplinary management, patients with biliary
tract cancer have a poor outcome. Only 20% of patients are eligible for surgical resection with …
tract cancer have a poor outcome. Only 20% of patients are eligible for surgical resection with …
SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma
AX Zhu, O Rosmorduc, TR Evans, PJ Ross… - … , vol. 33, num. 6, p. 559 …, 2014 - diposit.ub.edu
PURPOSE: To compare the clinical outcomes of sorafenib plus either erlotinib or placebo in
patients with advanced hepatocellular carcinoma (HCC) in a multicenter, multinational, …
patients with advanced hepatocellular carcinoma (HCC) in a multicenter, multinational, …
The gut microbiota and its relationship to diet and obesity: new insights
SF Clarke, EF Murphy, K Nilaweera, PR Ross… - Gut …, 2012 - Taylor & Francis
Obesity develops from a prolonged imbalance of energy intake and energy expenditure.
However, the relatively recent discovery that the composition and function of the gut microbiota …
However, the relatively recent discovery that the composition and function of the gut microbiota …